Eupraxia Pharmaceuticals Inc (EPRX.TO) has seen notable price movements and developments this week.
Eupraxia Pharmaceuticals Inc (EPRX.TO) experienced a price increase of 1.56% on the last trading day, bringing its weekly gain to 6.67%. This uptick comes amidst a backdrop of recent public offerings aimed at bolstering the company's financial position for clinical trials.
Investor takeaway: Investors should consider the implications of Eupraxia's recent capital raises and clinical developments while evaluating the stock's performance in the context of its technical indicators and market sentiment.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Eupraxia Pharmaceuticals Inc
EPRX.TO
EPRX.TO
Eupraxia Pharmaceuticals Inc
WealthAwesomeMarket cap
$586.64M
52W high
$12.86
52W low
$6.94
1W change
+6.67%
Beta
1.50
Analyst Price Targets
Based on analyst covering EPRX
Wall Street analysts forecast EPRX stock price to rise 79.1% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$16.33
+79.1% Upside
Current Price
C$9.12
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EPRX's historical volatility
30-Day Vol
58.3%
Annualized
90-Day Vol
57.5%
Annualized
Trend (90d)
-49.1%
Annualized drift
90d Mean
C$7.65
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$8.60 | C$7.04 – C$10.52 |
| 60 trading days | C$8.11 | C$6.11 – C$10.78 |
| 90 trading days | C$7.65 | C$5.40 – C$10.84 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Eupraxia Pharmaceuticals Inc's stock closed at C$9.07, up 1.56% on the day.
The stock has traded within a 52-week range of C$6.94 to C$12.86, currently sitting at 36% of its range, indicating potential volatility as it navigates market sentiment.
Bull case
The recent public offerings have strengthened Eupraxia's balance sheet, providing essential capital for ongoing clinical trials, especially for its lead program, EP-104GI. This financial boost is crucial for advancing their research and development efforts.
Bear case
Despite the recent gains, Eupraxia's stock remains below its 200-day moving average, and the company continues to report negative earnings. This raises concerns about its long-term viability and could make investors cautious.
Recent Price Action
Advertisement
Eupraxia Pharmaceuticals Inc (EPRX.TO) closed the last trading session at C$9.07, reflecting a 1.56% increase for the day and a 6.67% gain over the past week. Despite these positive movements, the stock has experienced a decline of 4.30% in the last month and is down 12.81% year-to-date.
Catalysts and Company News
There were no significant company news releases this week, but recent headlines indicate that Eupraxia has been active in raising capital through public offerings. On February 20, 2026, the company completed a public offering that raised approximately US$63.2 million, intended to support clinical trials for its lead program, EP-104GI. This funding is crucial for the company's ongoing research and development efforts.
Technical Picture
Eupraxia's stock is currently trading slightly below its 50-day moving average of C$9.11 and well below its 200-day moving average of C$9.73, indicating a bearish trend in the longer term. The stock has a beta of 1.50, suggesting higher volatility compared to the market. The latest trading volume was 32,895 shares, which is 1.11 times the 20-day average volume of 60,273 shares, indicating active trading.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
